Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

The gold rush for induced pluripotent stem cells

As the first commercial ventures are formed around induced pluripotent stem (iPS) cell research, who will have the freedom to operate commercially remains a big unknown. Sarah Webb reports.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Ebert, A.D. et al. Nature 457, 277–281 (2009).

    Article  CAS  Google Scholar 

  2. Dimos, J.T. et al. Science 321, 1218–1221 (2008).

    Article  CAS  Google Scholar 

  3. Soldner, F. et al. Cell 136, 964–977 (2009).

    Article  CAS  Google Scholar 

  4. Lee, G. et al. Nature 461, 402–406 (2009).

    Article  CAS  Google Scholar 

  5. Kim, D. et al. Cell Stem Cell 4, 472–476 (2009).

    Article  CAS  Google Scholar 

  6. Lin, T. et al. Nature Methods, published online 18 October, 2009, doi10.1038/nmeth.1393.

  7. Yu, J. et al. Science 324, 797–801 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Webb, S. The gold rush for induced pluripotent stem cells. Nat Biotechnol 27, 977–979 (2009).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing